Sinusoidal Obstruction Syndrome Following Myeloablative Therapy and Tranexamic Acid Treatment for Hemorrhage in Two Patients with Neuroblastoma
Adverse thromboembolic events following administration of the anti-fibrinolytic agent tranexamic acid (TA), used to prevent/treat excessive blood loss, are rare. We present the clinical course of two young patients (22 and 56 months) receiving busulfan/melphalan (Bu/Mel) high-dose chemotherapy with...
Saved in:
Main Authors: | Felix Zirngibl (Author), Carina Flemmig (Author), Peter Lang (Author), Annette Künkele (Author), Angelika Eggert (Author), Johannes H. Schulte (Author), Hedwig E. Deubzer (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
by: Michael Launspach, et al.
Published: (2021) -
Tranexamic acid to prevent early postpartum hemorrhages
by: Yu.E. Dobrokhotova, et al.
Published: (2019) -
Upfront consolidation treatment with 131I‐mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high‐risk neuroblastoma
by: Jianhua Feng, et al.
Published: (2020) -
Mutational topography reflects clinical neuroblastoma heterogeneity
by: Elias Rodriguez-Fos, et al.
Published: (2023) -
Inhibiting PHGDH with NCT-503 reroutes glucose-derived carbons into the TCA cycle, independently of its on-target effect
by: Birte Arlt, et al.
Published: (2021)